These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9394942)

  • 21. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
    Grant JE; Kim SW; Odlaug BL
    Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J; Pliszka SR
    J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An open trial of risperidone in young autistic children.
    Nicolson R; Awad G; Sloman L
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):372-6. PubMed ID: 9549957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anxiolytics, adrenergic agents, and naltrexone.
    Riddle MA; Bernstein GA; Cook EH; Leonard HL; March JS; Swanson JM
    J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):546-56. PubMed ID: 10230186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of a serious autistic disorder in a child with Naltrexone in an oral suspension form].
    Desjardins S; Doyen C; Contejean Y; Kaye K; Paubel P
    Encephale; 2009 Apr; 35(2):168-72. PubMed ID: 19393386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label use of placebos in the treatment of ADHD: a pilot study.
    Sandler AD; Bodfish JW
    Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron and zinc supplementation does not improve parent or teacher ratings of behavior in first grade Mexican children exposed to lead.
    Kordas K; Stoltzfus RJ; López P; Rico JA; Rosado JL
    J Pediatr; 2005 Nov; 147(5):632-9. PubMed ID: 16291354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bupropion hydrochloride in attention deficit disorder with hyperactivity.
    Conners CK; Casat CD; Gualtieri CT; Weller E; Reader M; Reiss A; Weller RA; Khayrallah M; Ascher J
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1314-21. PubMed ID: 8885585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effects of naltrexone on autistic behavior.
    Zingarelli G; Ellman G; Hom A; Wymore M; Heidorn S; Chicz-DeMet A
    Am J Ment Retard; 1992 Jul; 97(1):57-63. PubMed ID: 1497864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone.
    Scifo R; Cioni M; Nicolosi A; Batticane N; Tirolo C; Testa N; Quattropani MC; Morale MC; Gallo F; Marchetti B
    Ann Ist Super Sanita; 1996; 32(3):351-9. PubMed ID: 9028057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
    Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
    Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder.
    Niederhofer H; Staffen W; Mair A
    Hum Psychopharmacol; 2003 Jul; 18(5):389-93. PubMed ID: 12858327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of naltrexone in autistic children: report of two cases.
    Akkök F
    Turk J Pediatr; 1995; 37(1):19-23. PubMed ID: 7732604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.
    Fankhauser MP; Karumanchi VC; German ML; Yates A; Karumanchi SD
    J Clin Psychiatry; 1992 Mar; 53(3):77-82. PubMed ID: 1548248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.